Loading...
Loading...
BioLineRx
BLRX announced today that it has received approval from the French
regulatory authorities to commence a Phase I/II trial for BL-8020, an
orally available, interferon-free treatment for the Hepatitis C virus
(HCV). The study is an open-label trial to evaluate the efficacy, safety
and tolerability of BL-8020 in patients infected with HCV. It will be
conducted at two clinical sites in France and will include HCV-infected
patients of any genotype who have previously failed or relapsed
following treatment with the standard-of-care.
“We are excited about the upcoming initiation of clinical trials for our
first anti-HCV agent, BL-8020. The Phase I/II trial will be led by Prof.
Stanislas Pol, M.D., Ph.D,
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in